Why It Matters

The House Energy and Commerce Subcommittee on Health advanced 15 bills on June 25, mixing aggressive drug scheduling measures with health care transparency reforms. The markup revealed a bipartisan appetite for price transparency while also surfacing Democratic concerns about criminalizing drugs without sufficient scientific review.

The Big Picture

The legislative markup bundled three distinct policy clusters: drug scheduling and community safety, community health access and chronic disease prevention, and health care price transparency and Medicare Advantage reform.

President Trump has already signed two major bills from this panel into law, namely the Halt Fentanyl Act and the Support Act for Patients and Communities Reauthorization Act. The new markup extends that work, adding bills to combat xylazine and nitazenes while expanding transparency requirements across commercial and Medicare insurance plans.

The drug scheduling measures reflect growing concern about synthetic opioids. The White House's 2026 National Drug Control Strategy explicitly identifies synthetic opioids such as nitazenes and cutting agents like xylazine as being trafficked directly to drug dealers operating within the United States. A bipartisan coalition of 40 attorneys general, led by New York Attorney General Letitia James, formally urged Congress in March to pass the Combating Illicit Xylazine Act.

The transparency bills build on the administration's price transparency regulations. Recent Medicare Advantage reforms finalized in April 2025 required plans to report denial rates on their websites, inform enrollees of specific reasons for denials, and publicize internal coverage criteria. The new bills would extend these requirements further.

What They're Saying

The markup exposed a fundamental disagreement about process and substance. Rep. Diana DeGette (D-CO-1) expressed concern that the committee is marking up bills that would criminalize a class of drugs without adequate scientific review.

Rep. Frank Pallone Jr. (D-NJ-6) raised a different concern, stating that Republicans refused to extend the Affordable Care Act's enhanced premium tax credit. He noted that Americans are seeing their health care costs double or even triple in one year, and hospitals are closing service lines and facilities due to health care cuts. Pallone expressed disappointment that the markup does not include a provider ownership transparency bill for hospitals and physician practices, including for entities owned by private equity and venture capital firms. He stated that some bills make transparency reforms he will support, but he planned to force the issue of transparency legislation through amendments.

Markup Targets Synthetic Opioids

The drug scheduling component centers on two new controlled substance measures. The STOP Nitazenes Act targets one synthetic opioid. The Combating Illicit Xylazine Act would classify xylazine as a Schedule III under the Controlled Substances Act, while protecting legitimate use of xylazine in large animal veterinary medicine. The bill carries particular significance for Rep. H. Morgan Griffith (R-VA-9), the subcommittee chair whose congressional district is the largest cattle producing district east of the Mississippi and is home to two veterinary schools.

Fentanyl test strips and opioid reversal medications are proven interventions to save lives, and the markup includes legislation to make these tools more available. Tyler's Law requires the Department of Health and Human Services to study and issue guidance on whether hospitals should implement fentanyl testing in routine emergency department drug screens. This bill represents a more cautious approach than the scheduling measures, using research and guidance rather than criminal penalties.

Health Care Transparency Takes Center Stage

The transparency provisions dominated the markup. The Lower Cost, More Transparency Act empowers consumers and employers with data on the prices hospitals charge and the rates insurers pay. Several bills relate to prior authorization, and would allow individuals to see the percentage of health claims approved or denied in a plan year.

The Medicare Advantage Cost Transparency Act has bipartisan support and will require Medicare Advantage plans to report how much they pay for care, and how much beneficiaries pay for it. Bills under consideration will improve transparency of the Medicare Advantage program by requiring insurance companies to report data on supplemental benefits, spending on medical services, and broker compensation.

Another bill aims to bring transparency to how premium dollars are used by insurance plans. The medical loss ratio, created under the Affordable Care Act, is the percentage of premium dollars spent by an insurance company on medical care outside of administrative costs or profits.

Patients often make important medical decisions without clear information about costs they might face, provider network status, or alternative treatment options. Patients who carefully plan medical expenses can be surprised by bills that arrive weeks or months after receiving care. The transparency bills aim to address this information gap.

Community Health and Chronic Disease Prevention

A bill led by vice chair Diana Harshbarger (R-TN-1) would allow community health center funding to be used for nutrition education and chronic disease prevention initiatives. This reflects bipartisan support for community health center expansion, though the Trump administration's funding freeze on these centers created recent controversy. A judge blocked the freeze, but community health centers reported they were still unable to access money needed for salaries, utilities, and supplies after the funding freeze was blocked.

The Expanding Community Access to Health Services Act was also under consideration in the markup, addressing access gaps in underserved communities.

Political Stakes

For Democrats

The amendments signal Democratic concern about rushing drug scheduling legislation without adequate evidence about consequences, but the markup was a lost opportunity to require scientific review before criminalizing drug classes.

For the Administration

The bills build on the president's previous drug control initiatives and align with his administration's stated commitment to preventing drug use before it starts, and strengthening treatment that leads to recovery.

For the Public

The bills could provide meaningful cost information that's previously been unavailable, and Congress could impose controls without formal scheduling. The bipartisan nature of transparency bills suggests these measures have genuine legislative momentum.

What's Next

The bills now face full committee consideration and eventual floor votes. Senate Majority Leader John Thune and House Speaker Mike Johnson will coordinate on sequencing. The transparency bills likely face smoother passage than the drug scheduling measures, which may draw continued Democratic opposition focused on scientific review and equity concerns.

The Bottom Line

The markup reveals a Republican-controlled Congress pursuing health care transparency while Democrats prioritize process and equity, with drug scheduling measures creating the sharpest partisan divide.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article